UNSPSC 51381703: Acetaminophen glucuronide

This classification denotes an analgesic and antipyretic with the molecular formula C14H17NO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8BE7G9R76X, chemically known as .beta.-d-glucopyranosiduronic acid, 4-(acetylamino)phenyl, but more generally known as acetaminophen glucuronide, which bears US NIH Compound Identifier 83944. European Medicines Agency schedules acetaminophen glucuronide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG.

Most nations, for tariff purposes, schedule acetaminophen glucuronide under HS 29242990. SMILES: CC(=O)NC1CCC(CC1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O.

UNSPSC 51381703 Acetaminophen glucuronide is a Commodity code that encompasses pharmaceutical active pharmaceutical ingredients and finished pharmaceutical products procured by state and local health agencies, but recent state and local solicitations tagged under this code address naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products rather than acetaminophen glucuronide specifically. The mismatch between the code's nominal scope and the actual work being solicited suggests limited direct activity in the acetaminophen glucuronide category itself. State and local buyers under related pharmaceutical codes include county health departments (such as Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances administering procurement on behalf of participating state and local government facilities.

Recent solicitations show activity concentrated in Florida and Minnesota, with Texas engaged in preliminary market research. Seminole County, Florida issued IFB60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and July 1, 2026 contract effective date; vendors must work through AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson Co. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, representing exploratory procurement activity rather than a formal competitive solicitation.